lactobacillus casei F19 + lactobacillus acidophilus La5 + bifidobacterium lactis Bb12

This is a **probiotic combination** containing three well-researched bacterial strains: *lactobacillus casei F19*, *lactobacillus acidophilus La5*, and *bifidobacterium lactis Bb12*. These strains are all lactic acid and/or short-chain fatty acid producers that belong to the genera *Lactobacillus* and *Bifidobacterium*. The combination is intended to beneficially modulate intestinal microbiota, support digestive function, and promote immune health through multiple proposed mechanisms involving modulation of host mucosal immunity, competitive inhibition of pathogenic bacteria, enhancement of local and systemic IgA antibody responses, alteration of cytokine profiles, and possible improvement of epithelial barrier function. While there is evidence that such combinations can aid in **prevention or mitigation of diarrhea** (including rotavirus-associated diarrhea), reduce markers of gastrointestinal and systemic inflammation, and have positive effects in some inflammatory and metabolic disorders, precise efficacy and mechanisms depend on the specific strains, population, dosage, and clinical context. This combination is typically developed and used as a **dietary supplement** or medical food, not as a conventional pharmaceutical drug, and is not associated with a single developer or brand[1][2][3][4][5].

Other names

lactobacillus casei F19 + bifidobacterium animalis subsp. lactis Bb12 + lactobacillus acidophilus LA-5